Cerebrolysin
Evidence: B — Meaningful Human EvidenceCognitive / Neuro
Evidence Snapshot
What this grade covers
A for finished-product identity and foreign prescribing context; B/C for selected indication-specific randomized evidence; C/D for overall certainty; E for U.S. approval, generic-product equivalence, healthy nootropic use, neuroregeneration, or consumer dosing.
Regulatory Context
Cerebrolysin is marketed or authorized in some non-U.S. jurisdictions for neurologic indications. No FDA-approved U.S. product under the Cerebrolysin name was identified.
Research Takeaway
Cerebrolysin is a heterogeneous porcine-brain-derived peptide and amino-acid preparation rather than a single defined peptide molecule.
Evidence boundary: Evidence for one constituent cannot be assumed to describe the entire mixture.
See all 6 evidence claims →Quick Summary
Cerebrolysin is a proprietary porcine-brain-derived mixture of low-molecular-weight peptides and free amino acids studied in stroke, traumatic brain injury, and dementia. Human trials exist, but results are mixed and indication-specific.
Mechanism & Research Overview
Cerebrolysin is a complex biological preparation rather than a single defined peptide. Preclinical work proposes neurotrophic, anti-apoptotic, and neurorecovery effects, but the active components and clinically relevant targets are not fully defined.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Cerebrolysin is a heterogeneous porcine-brain-derived peptide and amino-acid preparation rather than a single defined peptide molecule.
Does not establish
Evidence boundary: Evidence for one constituent cannot be assumed to describe the entire mixture.
Sources: Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial; Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial
Supported
Randomized stroke trials have reported neurological or rehabilitation benefits in some populations, but results across studies and outcomes are inconsistent.
Does not establish
Evidence boundary: Positive individual trials do not establish a uniformly effective acute-stroke treatment.
Sources: Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial; Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial; Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial; Cerebrolysin for acute ischaemic stroke
Supported
Cerebrolysin is not an FDA-approved drug in the United States, and FDA has taken enforcement action involving compounded Cerebrolysin products that did not qualify for cited compounding exemptions.
Does not establish
Evidence boundary: Use or approval in other countries does not establish U.S. FDA approval.
Sources: Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine - Warning Letter
Supported
Controlled trials generally report tolerability comparable to placebo, but systematic review evidence remains uncertain for serious clinical outcomes and should not be simplified into a blanket safety claim.
Does not establish
Evidence boundary: Trial tolerability does not establish safety of unapproved imported or compounded products.
Sources: Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial; Cerebrolysin for acute ischaemic stroke
Supported
The stroke literature does not establish Cerebrolysin as a proven cognitive enhancer, anti-aging agent, or treatment for otherwise healthy individuals.
Does not establish
Evidence boundary: Disease-specific trial findings cannot be extrapolated to enhancement uses.
Sources: Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial; Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial; Cerebrolysin for acute ischaemic stroke
Supported
Only exact dosing from a named clinical trial may appear under Study/Trial Dosing; no consumer infusion, injection, cycling, or reconstitution recommendations may be provided.
Does not establish
Evidence boundary: Published trial regimens are descriptive evidence, not individualized treatment guidance.
Sources: Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial; Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Foreign prescribing information identifies contraindications or cautions involving hypersensitivity to components, epilepsy, and severe renal impairment. Reported or discussed adverse effects include dizziness, headache, sweating or feeling hot, nausea, agitation, anxiety, injection or infusion reactions, and tachycardia, blood-pressure change, or arrhythmia with rapid administration; possible seizure-related concerns in susceptible patients.Safety Consideration
Evidence is mixed across stroke, dementia, and brain-injury indications, and positive findings are not uniformly replicated.Safety Consideration
A severe anaphylaxis case has been published; rare hypersensitivity risk cannot be estimated from trials.Safety Consideration
It is a heterogeneous animal-derived preparation, so product identity and manufacturing consistency cannot be inferred from catalog naming.Safety Consideration
Additional uncertainties include porcine biological starting material and manufacturing consistency, batch comparability, immune or hypersensitivity reactions, sterility and endotoxin control, interactions with antidepressants, anticoagulants, thrombolytics, antiseizure drugs, and other CNS agents, limited evidence in pregnancy, children, severe renal disease, and long-term repeated cycles, and risk of delaying proven emergency stroke or TBI care.
Research Areas Being Studied
Research areas discussed on this page reflect the Cognitive / Neuro category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial (2016):
- Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (2012):
- Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial (2005):
- CAPTAIN II Acute Brain Injury Trial ():
- Cerebrolysin Dose-Ranging Alzheimer Trial ():
- Cerebrolysin in Vascular Dementia ():
- Cerebrolysin Neurorecovery After Moderate-Severe TBI ():
- Cerebrolysin Plus Alteplase Randomized Trial ():
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial | 2016 | Patients in the early rehabilitation phase after ischemic stroke | The CARS trial reported improved motor and global outcomes during early stroke rehabilitation with Cerebrolysin versus placebo. The study was exploratory and relatively small.
| The trial reported a generally comparable safety profile, but replication and independent synthesis remain important. | |
| Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial | 2012 | 1,070 adults with acute ischemic stroke | This large acute-stroke trial did not establish a broad unequivocal efficacy result across the full population, illustrating inconsistency within the clinical evidence base.
| Adverse-event rates were broadly similar in the published trial, but the study does not establish broad efficacy. | |
| Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial | 2005 | Adults treated within 24 hours of acute stroke | Patients with acute stroke were randomized to Cerebrolysin or placebo with background therapy. Early neurological improvement signals were reported, but the study does not establish U.S. approval.
| The source reported tolerability within the study; it was not powered to establish rare adverse-event risks. | |
| CAPTAIN II Acute Brain Injury Trial | Randomized and controlled studies of the CAPTAIN program report signals of improved multidimensional recovery after moderate-to-severe TBI. | ||||
| Cerebrolysin Dose-Ranging Alzheimer Trial | In a 192-participant randomized trial, the global CIBIC+ measure favored Cerebrolysin at week 12; the abstract did not report a significant ADAS-Cog treatment difference; baseline imbalances were present; adverse events were common in both groups. | ||||
| Cerebrolysin in Vascular Dementia | Some randomized studies report improvements in cognition and global function in mild-to-moderate vascular dementia. Evidence quality, replication, and applicability to modern diagnostic criteria remain limitations. | ||||
| Cerebrolysin Neurorecovery After Moderate-Severe TBI | The CAPTAIN program reports signals of improved multidimensional recovery after moderate-to-severe TBI. The evidence does not establish routine use in all TBI, benefit after remote concussion, healthy cognitive enhancement, prevention of chronic traumatic encephalopathy, or a self-directed recovery protocol. | ||||
| Cerebrolysin Plus Alteplase Randomized Trial | A randomized study combining Cerebrolysin with alteplase found the combination was tolerable but did not improve the principal day-90 outcome. Short-term neurological measures favored treatment during the exposure period. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine - Warning Letter | 2021 | FDA stated that compounded Cerebrolysin products at the cited firm did not meet conditions for section 503A exemptions and were not components of FDA-approved drugs. | |||
| FDA Tailor Made Compounding Warning Letter | 2020 | A 2020 FDA warning letter stated that a pharmacy's compounded Cerebrolysin products were not components of FDA-approved human drugs, were not supported by an applicable USP/NF monograph, and were not on the 503A Bulks List at that time. The letter also documented serious sterile-production deficiencies at that facility. This does not establish that every foreign authorized finished product is adulterated -- it establishes that the cited compounded U.S. products were ineligible for 503A exemptions and lacked FDA approval. | |||
| Tailor Made Compounding LLC - Warning Letter | 2020 | FDA identified compounded IGF1-LR3, Cerebrolysin, PEG-MGF, and Melanotan II products that did not qualify for cited section 503A exemptions and were not components of FDA-approved human drugs. | |||
| Cerebrolysin Product and Prescribing Information | Cerebrolysin has foreign prescribing information for selected cerebrovascular, dementia, and brain-injury indications, including hypersensitivity, epilepsy, and severe-renal-impairment contraindications/cautions. Foreign authorization does not create U.S. FDA approval. Used for identity and foreign-label context only. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Cerebrolysin for acute ischaemic stroke | 2023 | Randomized trials in acute ischemic stroke | The updated Cochrane review found no clear mortality benefit and continuing uncertainty for important clinical outcomes. It provides a conservative evidence boundary against overgeneralizing positive individual trials. | This secondary synthesis highlights uncertainty and potential safety signals rather than confirming broad benefit. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-07-30.
Follow research updates for Cerebrolysin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.